Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: Correlation with plaque composition

Atherosclerosis

Volumn 208, Issue 2, 2010, Pages 376-381

  Cyrus, Tillmann ^b   Ding, Tao ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Animal models; Atherosclerosis; Prostaglandins; Thromboxanes

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; THROMBOXANE A2; THROMBOXANE RECEPTOR; THROMBOXANE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ATHEROSCLEROSIS; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY FATS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOHISTOCHEMISTRY; INTRAMOLECULAR OXIDOREDUCTASES; LIPIDS; MALE; MICE; MICE, KNOCKOUT; PROSTAGLANDINS; RECEPTORS, THROMBOXANE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOXANE-A SYNTHASE; THROMBOXANES;

EID: 75049084888     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.008     Document Type: Article

References (28)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-872
2. Dogne J.M., Hanson J., and Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherosclerosis. Trends Pharmacol Sci 26 (2005) 639-644
3. Belton O., Byrne D., Kearny D., Leahy A., and Fitzgerald D.J. Cyclo-oxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
4. Pratico D., Cyrus T., Li H., and Fitzgerald G.A. Endogenous biosynthesis of thromboxane and prostacyclin in two distinct murine models of atherosclerosis. Blood 96 (2000) 3823-3826
5. Hamberg M., Svensson J., and Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72 (1988) 761-767
6. Shen R.F., and Tai H.H. Thromboxanes: synthase and receptors. J Biomed Sci 5 (1998) 153-172
7. Yu I.S., Lin S.R., Huang C.C., et al. TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood 104 (2004) 135-142
8. Praticò D. Prostanoids and isoprostanoids pathways in atherogenesis. Atherosclerosis 201 (2008) 8-16
9. Needleman P., Moncada S., Bunting S., Vane J.R., Hamberg M., and Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 261 (1976) 558-560
10. Antithrombotic Trialist' Collaboration. Collaborative meta-analysis of randomized clinical trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 324 (2002) 71-86
11. Cyrus T., Yao Y., Tung L., and Praticò D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor deficient mice. Circulation 106 (2002) 1282-1287
12. McClelland S., Gawaz M., Kennerknecht E., et al. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis 202 (2009) 84-91
13. Cyrus T., Yao Y., Ding T., Dogne J.M., and Praticò D. A novel thromboxane receptor antagonist and synthase inhibitor, BM573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur J Pharmacol 561 (2007) 105-111
14. Kobayashi T., Tahara Y., Matsumoto M., et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114 (2004) 784-794
15. Praticò D., and Dogne J.M. Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine. Circulation 112 (2005) 1073-1079
16. Metha J., and Roberts A. Human vascular tissues produce thromboxane as well as prostacyclin. Am J Physiol 244 (1983) R839-844
17. Cyrus T., Yao Y., Ding T., Dogne J.M., and Praticò D. Thromboxane receptor blockade improves the anti-atherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood 109 (2007) 3291-3296
18. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100 (1997) 2028-2034
19. Chinnici C., Yao Y., and Praticò D. The 5-Lipoxygenase enzymatic pathways in the mouse brain: young versus old. Neurobiol Aging 28 (2007) 1457-1462
20. Cyrus T., Yao Y., Tung L.X., and Praticò D. Atherosclerotic plaque stabilization in low-density lipoprotein receptor deficient mice by low-dose aspirin. Atherosclerosis 184 (2006) 8-14
21. Van Eck M., Hoekstra M., Hildebrand R.B., et al. Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscl Thromb Vasc Biol 27 (2007) 2413-2419
22. Dogne J.M., Hanson J., Leval X., et al. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 12 (2006) 903-923
23. Schonbeck U., Sukhova G.K., Graber P., Coulter S., and Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281-1291
24. Praticò D., Cyrus T., Zhang Z.B., Li H., and FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in LDL receptor knockout mice. Proc Natl Acad Sci USA 98 (2001) 3358-3363
25. Tangirala R.K., Rubin E.M., and Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic region and the entire aorta, and differences in the extent of lesions between sexes in LDL-receptor-deficient and apolipoprotein E-deficient mice. J Lip Res 36 (1995) 2320-2328
26. Paul A., Yechoor V., Raja R., Li L., and Chan L. Microarray gene profiling of laser-captured cells: a new tool to study atherosclerosis in mice. Atherosclerosis 200 (2008) 257-263
27. Moulton K.S., Vakili K., Zukarowski D., et al. Inhibition of neovascularization reduces macrophages accumulation and progression of advanced arteriosclerosis. Proc Natl Acad Sci USA 100 (2003) 4736-4741
28. Cayatte A.J., Du Y., Oliver-Krasinski J., Lavielle G., Verbeuren T.J., and Cohen R.A. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscl Thromb Vasc Biol 20 (2000) 1724-1728